Author:
Bryan R T,Shimwell N J,Wei W,Devall A J,Pirrie S J,James N D,Zeegers M P,Cheng K K,Martin A,Ward D G
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. Abe H, Kuroki M, Imakiire T, Yamauchi Y, Yamada H, Arakawa F, Kuroki M (2002) Preparation of recombinant MK-1/Ep-CAM and establishment of an ELISA system for determining soluble MK-1/Ep-CAM levels in sera of cancer patients. J Immunol Methods 270: 227–233.
2. Allory Y, Beukers W, Sagrera A, Flández M, Marqués M, Márquez M, van der Keur K, Dyrskjot L, Lurkin I, Vermeij M, Carrato A, Lloreta J, Lorente J, Carrillo-de Santa Pau E, Masius R, Kogevinas M, Steyerberg E, van Tilborg A, Abas C, Orntoft T, Zuiverloon T, Malats N, Zwarthoff E, Real F (2013) Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol 110 (3): 668–678.
3. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J, Rouprêt M European Association of Urology (2011) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59: 997–1008.
4. Brunner A, Prelog M, Verdorfer I, Tzankov A, Mikuz G, Ensinger C (2008) EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladder. J Clin Pathol 61: 307–310.
5. Burger M, Catto J, Dalbagni G, Grossman H, Herr H, Karakiewicz P, Kassouf W, Kiemeney L, La Vecchia C, Shariat S, Lotan Y (2013) Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63: 234–241.
Cited by
38 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献